Homepage
Full 18-step deep-dive · ~20–30 min · a member feature.
No report run on this ticker yet
Only preliminary foundational data below
Sign in to run a fresh report
Free · results in ~10 min
For AI assistants & researchers — machine-readable summary of this page
What this page is: Delvantic's full research page for Absci Corporation (ABSI) — AI-driven forensic equity research: mechanical valuation models (DCF, EPV, anchored-PE, scenario) plus three independent AI lenses (Quality / Value / Sentiment). Everything below is rendered server-side; you are not missing content that requires JavaScript. All scores are predictions and research opinions, not financial advice.
Page map (sections in order; each card carries a stable
reference-name attribute you can cite):
profile-header/price-overview— company profile, live quote, market capextended-analysis— the core: three AI lens reads with findings, scores, and the analyst memofuture-predictions— our forward price-band predictionsmarket-narrative/ai-findings/gpt-critique— narrative context, cross-model findings, and an adversarial critique of our own analysis (near the end of the document)- Members-only sections (render as login gates for anonymous readers):
price-history,income-trend,key-metrics,financials(statement tables),insider-trading. The analysis above is public; the raw data tables require a free account.
More for machine readers: site briefing at
/llms.txt ·
any ticker resolves at delvantic.com/stock/TICKER ·
raw inputs are public-company filings and market data (via licensed data feeds);
every model, score, lens read, and prediction on this page is Delvantic's own analysis.
Healthcare · Biotechnology
Vancouver, WA 98683, United States
absci.com
Price
$8.93
Market Cap
$1.5B
Employees
140
Beta
2.43
Avg Volume
4,079,130
CEO
Mr. Sean McClain
Absci Corporation is a clinical-stage biopharmaceutical company that specializes in using generative artificial intelligence to design and create biologic drugs. The company operates a data-first drug creation platform that integrates AI models with scalable wet lab technologies to discover, optimize, and produce therapeutic proteins and antibodies. Absci’s integrated platform is used to identify novel drug targets, generate and engineer therapeutic candidates, and develop production cell lines in a unified process, aiming to streamline early-stage discovery and development workflows for biologics. Its technology leverages synthetic biology and high-throughput experimentation to predict, design, build, and screen large libraries of biologic drug candidates for partners in the biopharmaceutical industry. Absci focuses today on advancing AI-designed antibody therapeutics and other biologics across multiple disease areas, collaborating with pharmaceutical and biotechnology companies globally. Founded in 2011 and headquartered in Vancouver, Washington, Absci plays a specialized role at the intersection of biotechnology, artificial intelligence, and drug discovery.
Runs with full report
Earnings Schedule
Checked daily · calendar updated Aug 9 No upcoming print on the calendar yet — companies typically confirm a few weeks ahead. Last print was May 7, 2026.
EPS surprise history — vs analyst consensus · 5 prints of vendor history
+4.8%
Nov '25
+1.9%
Jan '26
-35.3%
Mar '26
+9.1%
Apr '26
+5.0%
May '26
| Print date | EPS est. | EPS actual | Revenue est. | Revenue actual |
|---|---|---|---|---|
| May 7, 2026 | $-0.20 | $-0.19 +5.0% | — | — |
| Apr 14, 2026 | $0.44 | $0.48 +9.1% | — | — |
| Mar 24, 2026 | $-0.17 | $-0.23 -35.3% | — | — |
| Jan 29, 2026 | $6.45 | $6.57 +1.9% | — | — |
| Nov 12, 2025 | $-0.21 | $-0.20 +4.8% | — | — |
Green = beat the estimate, red = missed. An earnings print is the fastest way a thesis changes — our designations should be re-read after each one.
Recent SEC Filings
| Filed | Form | Document |
|---|---|---|
| Aug 7, 2026 | 4 | View |
| Aug 7, 2026 | 3 | View |
| Jul 6, 2026 | 4 | View |
| Jun 26, 2026 | 4 | View |
| Jun 24, 2026 | 8-K | View |
| Jun 24, 2026 | 424B5 | View |
| Jun 24, 2026 | 8-K | View |
| Jun 15, 2026 | 4/A | View |
| Jun 11, 2026 | 4 | View |
| Jun 8, 2026 | 4 | View |
| Jun 8, 2026 | 4 | View |
| Jun 8, 2026 | 4 | View |
Filings link to the SEC’s EDGAR system. Annual/quarterly reports (10-K, 10-Q, 20-F) carry the full story; 8-K/6-K current reports are the fastest signal that something material happened.
Price Overview
Last updated: Aug 9, 2026 3:26am (just now)
Current data · timestamped when a report runs
$8.93
Change · Aug 9
+0.63 (+7.59%)
Day Range
$8.47 – $8.97
52-Week Range
$2.24 – $12.06
50-Day MA
$8.44
200-Day MA
$4.74
Volume
2,188,700.00
Share Structure
Outstanding
155,350,135.00
Float
148,719,392.00
Free Float
95.7%
High free float
— 95.7% of shares trade freely, ~4.3% held by insiders/institutions
Very liquid — most shares trade freely. Low insider ownership can mean less management alignment, but makes large position sizing straightforward.
Price History (1 Year)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
TD Twelve Data statement
HEX SEC filing
P/E Ratio (Price per dollar of earnings)
HEXStock Price / EPS (Diluted)
-10.63
Stock Price: $8.93
EPS (Diluted): -0.84
EPS (Diluted): -0.84
P/B Ratio (Price vs net asset value)
HEXStock Price / Book Value Per Share
6.45
Stock Price: $8.93
Total Equity: $189.45M
Shares: 136,776,885
Total Equity: $189.45M
Shares: 136,776,885
EV/EBITDA (Total value vs operating profit)
HEXEnterprise Value / EBITDA
-12.40
Market Cap: $1.51B
Total Debt: $0.00
Cash: $20.03M
EBITDA: -$108.58M
Total Debt: $0.00
Cash: $20.03M
EBITDA: -$108.58M
Enterprise Value (Takeover price (cap + debt - cash))
HEXMarket Cap + Total Debt - Cash
$1.3B
Market Cap: $1.51B
Total Debt: $0.00
Cash: $20.03M
Total Debt: $0.00
Cash: $20.03M
Gross Margin (Revenue left after direct costs)
HEXGross Profit / Revenue
—
Gross Profit: N/A
Revenue: N/A
Revenue: N/A
Missing from API: Gross Profit, Revenue
Operating Margin (Revenue left after all operations)
HEXOperating Income / Revenue
—
Operating Income: -$120.32M
Revenue: N/A
Revenue: N/A
Missing from API: Revenue
Net Margin (Revenue left as actual profit)
HEXNet Income / Revenue
—
Net Income: -$115.18M
Revenue: N/A
Revenue: N/A
Missing from API: Revenue
ROE (Profit from shareholder equity)
HEXNet Income / Total Equity
-60.8%
Net Income: -$115.18M
Total Equity: $189.45M
Total Equity: $189.45M
ROIC (Profit from all invested capital)
HEXNOPAT / Invested Capital
-71.1%
Operating Income: -$120.32M
Tax Rate: -0.1%
Equity: $189.45M
Total Debt: $0.00
Cash: $20.03M
Tax Rate: -0.1%
Equity: $189.45M
Total Debt: $0.00
Cash: $20.03M
Zero debt — invested capital = equity minus cash (very efficient)
Current Ratio (Can it pay short-term bills)
HEXCurrent Assets / Current Liabilities
6.57
Current Assets: $149.57M
Current Liabilities: $22.77M
Current Liabilities: $22.77M
Debt/Equity (Leverage — debt vs equity)
HEXTotal Debt / Total Equity
0.00
Short-Term Debt: $0.00
Long-Term Debt: $0.00
Total Debt: $0.00
Total Equity: $189.45M
Long-Term Debt: $0.00
Total Debt: $0.00
Total Equity: $189.45M
Zero debt — this company carries no debt obligations. Strongest possible score.
Rev/Share (Top-line per share)
HEXRevenue / Shares Outstanding
—
Revenue: N/A
Shares: 136,776,885
Shares: 136,776,885
Missing from API: Revenue
Book Value/Share (Net assets per share)
HEX(Total Assets - Total Liabilities) / Shares
$1.39
Total Equity: $189.45M
Shares: 136,776,885
Shares: 136,776,885
FCF/Share (Real cash generated per share)
HEX(Operating Cash Flow + CapEx) / Shares
$-0.69
Operating CF: -$92.93M
CapEx: -$1.11M
Shares: 136,776,885
CapEx: -$1.11M
Shares: 136,776,885
CapEx is negative (outflow) — added to OCF to get FCF
Div Yield (Annual income from holding)
TDLast Annual Dividend / Stock Price
—
Last Dividend: $0.00
Stock Price: $8.93
Stock Price: $8.93
Payout Ratio (Earnings paid out as dividends)
HEXDividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: -$115.18M
Net Income: -$115.18M
Dividends paid not available in cash flow statement
Income Statement (Annual)
Last updated: Aug 7, 2026 4:16am (1d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $4.8M | $5.7M | $5.7M | $4.5M | — |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Expenses | $80.0M | $112.5M | $121.2M | $113.4M | $123.1M |
| Operating Income | -$75.2M | -$106.8M | -$115.5M | -$108.9M | -$120.3M |
| Net Income | -$101.0M | -$104.9M | -$110.6M | -$103.1M | -$115.2M |
| EBITDA | -$68.6M | -$93.7M | -$101.5M | -$95.5M | -$108.6M |
| EPS | $-2.08 | $-1.15 | $-1.20 | $-0.94 | $-0.84 |
| EPS (Diluted) | $-2.08 | $-1.15 | $-1.20 | $-0.94 | $-0.84 |
Balance Sheet (Annual)
Last updated: Aug 7, 2026 4:16am (1d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $252.6M | $60.0M | $72.4M | $41.2M | $20.0M |
| Total Current Assets | $273.1M | $186.9M | $120.6M | $133.8M | $149.6M |
| Total Assets | $426.2M | $321.0M | $217.3M | $213.6M | $216.3M |
| Current Liabilities | $33.9M | $30.3M | $29.6M | $28.7M | $22.8M |
| Long-Term Debt | $3.5M | $10.9M | $7.9M | $4.0M | — |
| Total Liabilities | $60.1M | $46.6M | $41.1M | $34.5M | $26.8M |
| Total Equity | $366.1M | $274.4M | $176.2M | $179.1M | $189.4M |
| Retained Earnings | -$191.0M | -$295.9M | -$406.5M | -$509.6M | -$624.8M |
Cash Flow (Annual)
Last updated: Aug 7, 2026 4:16am (1d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$60.6M | -$81.3M | -$64.6M | -$72.4M | -$92.9M |
| Capital Expenditure | -$38.0M | -$16.2M | $-860,000 | $-404,000 | -$1.1M |
| Free Cash Flow | -$98.6M | -$97.5M | -$65.5M | -$72.8M | -$94.0M |
| Acquisitions (net) | -$28.1M | -$8.0M | $0 | — | — |
| Net Debt Issued / (Repaid) | -$1.6M | -$4.7M | -$3.0M | -$3.4M | -$3.1M |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | — | — | — | — | — |
| Net Change in Cash | $208.2M | -$203.1M | $12.8M | -$31.5M | -$37.1M |
Growth Trends (YoY %)
Last updated: Aug 7, 2026 4:16am (1d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +20.2% | -0.5% | -20.7% | — |
| Gross Profit Growth | — | — | — | — |
| Operating Income Growth | -41.9% | -8.2% | +5.7% | -10.5% |
| Net Income Growth | -3.9% | -5.4% | +6.7% | -11.7% |
| EBITDA Growth | -36.6% | -8.3% | +5.9% | -13.7% |
Insider Trading (Recent)
Type codes
PPurchase
SSale
AAward / grant
MOption exercise
FIn-kind (tax)
CConversion
GGift
DReturn to issuer
All SEC Form 4 codes
Open market
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
Compensation (Rule 16b-3)
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
Derivatives
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
Other exempt
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
Other
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-06-30 | Szela Mary T | P-Purchase | 12,900.00 | $11.54 | $148,866 |
Industry Benchmarks
Compares ABSI against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Narrative Economics
The story the market is telling about this stock — the intangible X-factor
(founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond
what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for ABSI — it's generated by the pipeline (
market-narrative step).
Claude Reading
No AI findings yet for ABSI — they're generated by the
pipeline (
ai-findings step) when a report is run on this ticker.
GPT Reading
No GPT reading yet for ABSI — it's generated by the
pipeline (
gpt-critique step) after the other Big-3 seats, when a
report is run on this ticker.
Grok Reading
No Grok reading yet for ABSI — it's generated by the
pipeline (
grok-critique step) alongside the other Big-3 seats, when a
report is run on this ticker.
Advanced Analysis Forensic deep-dive · three lenses
Character & Durability Scorecard
Ten long-horizon business-character traits the Quality / Value / Sentiment lenses don’t break out, scored 1–10.
No scorecard yet for ABSI — the ten traits are scored by the
pipeline (
ext-scorecard step) when a report is run on this ticker.
No community reviews yet for ABSI.
Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · twelvedata
v1.1.515 · 9f7cac68 · 2026-08-08 13:09:58